946147-63-3

Upstream product

• 80058-84-0 4-bromo-2,6-diisopropylaniline 
• 24544-04-5 2,6-diisopropylbenzenamine 

Downstream Products

• 958007-24-4 (4-bromo-2,6-diisopropylphenyl)bis(2,4,6-triisopropylphenyl)phosphine 
• 1211107-19-5 bis(4-bromo-2,6-diisopropylphenyl)chlorophosphine 
• 1211107-21-9 tris(4-bromo-2,6-diisopropylphenyl)phosphine 
• 946147-64-4 2,6-diisopropyl-4-bromobenzaldehyde 
• 946147-66-6 2,6-diisopropyl-4-bromophenylacetaldehyde 

Relevant academic research and scientific papers

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY

In one aspect, compounds of Formula A, or a pharmaceutically acceptable salt thereof, are featured (Formula A) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

Enhanced Separation Concept (ESC): Removing the Functional Subunit from the Electrode by Molecular Design

A new concept to improve the reliability of functional single molecule junctions is presented using the E-field triggered switching of FeIIbis-terpyridine complexes in a mechanically controlled break junction experiment as model system. The complexes comprise a push-pull ligand sensing the applied E-field and the resulting distortion of the FeII ligand field is expected to trigger a spin-crossover event reflected in a sudden jump of the transport current. By molecular engineering, the active centre of the complex is separated from the gold electrodes in order to eliminate undesired side-effects. Two aspects are considered to isolate the central metal ion, namely the spacing by introducing additional alkynes, and the steric shielding achieved by bulky isopropyl groups. With this small series of model complexes, a pronounced correlation is observed between the occurrence of bistable junctions and the extent of separation of the central metal ion, affirming the hypothesized Enhanced Separation Concept (ESC).

SULPHONAMIDES AND COMPOSITIONS THEREOF FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: wherein the variables shown in Formula AA can be as defined anywhere herein. Compounds AA are modulators of NLRP1 and/or NLRP3

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g. osteoarthritis, osteoporosis or osteopetrosis disorders), eye disease (e.g. glaucoma or macular degeneration), a disease caused by viral infection (e.g. HIV or AIDS), an autoimmune disease (e.g. Rheumatoid Arthritis, Systemic Lupus Erythematosus or Autoimmune Thyroiditis), cancer or aging.

High-Performance Dibenzoheteraborin-Based Thermally Activated Delayed Fluorescence Emitters: Molecular Architectonics for Concurrently Achieving Narrowband Emission and Efficient Triplet–Singlet Spin Conversion

Thermally activated delayed fluorescence (TADF) materials, which enable the full harvesting of singlet and triplet excited states for light emission, are expected as the third-generation emitters for organic light-emitting diodes (OLEDs), superseding the conventional fluorescence and phosphorescence materials. High photoluminescence quantum yield (ΦPL), narrow-band emission (or high color purity), and short delayed fluorescence lifetime are all strongly desired for practical applications. However, to date, no rational design strategy of TADF emitters is established to fulfill these requirements. Here, an epoch-making design strategy is proposed for producing high-performance TADF emitters that concurrently exhibiting high ΦPL values close to 100%, narrow emission bandwidths, and short emission lifetimes of ≈1 μs, with a fast reverse intersystem crossing rate of over 106 s?1. A new family of TADF emitters based on dibenzoheteraborins is introduced, which enable both doped and non-doped TADF-OLEDs to achieve markedly high external electroluminescence quantum efficiencies, exceeding 20%, and negligible efficiency roll-offs at a practical high luminance. Systematic photophysical and theoretical investigations and device evaluations for these dibenzoheteraborin-based TADF emitters are reported here.

Organic electroluminescent materials and devices

Compounds comprising phosphorescent metal complexes comprising cyclometallated imidazo[1,2-f]phenanthridine and diimidazo[1,2-a:1′,2′-c]quinazoline ligands, or isoelectronic or benzannulated analogs thereof, are described. Organic light emitting diode devices comprising these compounds are also described.

METAL COMPLEXES OF CYCLOMETALLATED IMIDAZO[1,2-f]PHENANTHRIDINE AND DIIMIDAZO[1,2-A:1',2'-C]QUINAZOLINE LIGANDS AND ISOELECTRONIC AND BENZANNULATED ANALOGS THEREOF

The present invention refers to-imidazo [1,2-f] the dee trillion which gets torn phenylphenanthridines and [1,2-a:1 ', 2' -c] quinazoline ligands, or its isoelectronic characteristic and or phosphor including analogue relates to compounds including metal complex. Furthermore, the present invention refers to these compounds including relates organic light emitting diode devices. (by machine translation)

Phosphorescent condensed ring carbene metal complexes for use in organic light emitting devices

The invention relates to a compound comprising a phosphorescent metal complex comprising a monoanionic, bidentate ligand; wherein the metal is selected from the group consisting of the non-radioactive metals with atomic numbers greater than 40; and wherein the bidentate ligand comprises a carbene donor and may be linked with other ligands to comprise a tridentate, tetradentate, pentadentate or hexadentate ligand.

Synthesis and redox properties of crowded triarylphosphines carrying a nitroxide radical and related compounds

Crowded triarylphosphines carrying a nitroxide radical were synthesized to investigate intramolecular interaction between the crowded triarylphosphine redox centers and a neutral radical. A crowded triarylphosphine carrying a bromoaryl group was developed as a key synthetic intermediate. Lithiation of the (bromoaryl)phosphine, followed by reaction with 2-methyl-2-nitrosopropane, afforded a crowded triarylphosphine carrying a nitroxide after aerobic oxidation. Similar procedure using isoamyl nitrite (isoamyl = 3-methylbutyl) gave nitroxide and azobenzene derivatives with two crowded triarylphosphine moieties. The azobenzene derivative was alternatively prepared by photolysis of the corresponding (azidoaryl)phosphine. EPR spectra of the nitroxide radicals showed hyperfine couplings with 31P nuclei, which were larger than previously reported phosphinoaryl nitroxide radicals. Cyclic voltammograms of the newly synthesized triarylphosphines showed reversible redox waves corresponding to the phosphorus redox centers. The two triarylphosphine moieties connected by a nitroxide linkage showed a reversible two-step oxidation reflecting considerable interaction between the phosphorus redox sites across the nitroxide linkage. Oxidation of the crowded triarylphosphines carrying a nitroxide and photolysis of the chemically oxidized (azidoaryl)phosphme was studied by EPR spectroscopy.